Unknown PHASE3 INTERVENTIONAL 3-arm NCT00132743

Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) (CLEVER)

Sponsor: Joselyn Cerezo, MD

Conditions Atherosclerosis Cardiovascular Diseases Peripheral Vascular Diseases

Interventions Cilostazol Stent Supervised Exercise Therapy

Updated 7 times since 2017 Last updated: Apr 24, 2013 Started: Feb 28, 2007 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00132743, this PHASE3 trial focuses on Atherosclerosis and Cardiovascular Diseases and remains ongoing. Sponsored by Joselyn Cerezo, MD, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Joselyn Cerezo, MD
National Heart, Lung, and Blood Institute (NHLBI)

Data source: Rhode Island Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandria, United States , Ann Arbor, United States , Asheville, United States , Baltimore, United States , Charleston, United States , Chicago, United States , Des Moines, United States , Detroit, United States , Evans, United States , Halifax, Canada and 16 more locations